Daily peritoneal administration of sodium pyrophosphate in a dialysis solution prevents the development of vascular calcification in a mouse model of uraemia

The high rate of cardiovascular mortality in patients with end-stage renal disease (ESRD) is a significant barrier to improved life expectancy. Unique in this population is the marked development and aggressive worsening of vascular calcification (VC). Pyrophosphate (PPi), an endogenous molecule, ap...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nephrology, dialysis, transplantation dialysis, transplantation, 2011-10, Vol.26 (10), p.3349-3357
Hauptverfasser:	RISER, Bruce L, BARRETO, Fellype Carvalho, HOLMES, Clifford J, MASSY, Ziad A, REZG, Raja, VALAITIS, Paul W, COOK, Chyung S, WHITE, Jeffrey A, GASS, Jerome H, MAIZEL, Julien, LOUVET, Loic, DRUEKE, Tilman B
Format:	Artikel
Sprache:	eng
Schlagworte:	Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Animals Apolipoproteins E - physiology Biological and medical sciences Calcium - metabolism Dialysis Solutions - pharmacokinetics Dialysis Solutions - therapeutic use Diphosphates - administration & dosage Diphosphates - pharmacokinetics Emergency and intensive care: renal failure. Dialysis management Female Glomerulonephritis Half-Life Intensive care medicine Male Medical sciences Mice Mice, Knockout Nephrology. Urinary tract diseases Nephropathies. Renovascular diseases. Renal failure Peritoneal Dialysis - adverse effects Rats Rats, Sprague-Dawley Renal Insufficiency - complications Renal Insufficiency - therapy Tissue Distribution Uremia - drug therapy Uremia - etiology Vascular Calcification - etiology Vascular Calcification - prevention & control
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!